Latest News

NiSource Provides Update on Implementation of Safety Steps Across Its Low-Pressure Systems

Friday February 22 nd 2019

MERRILLVILLE, Ind., Feb. 22, 2019 /PRNewswire/ — NiSource Inc. (NYSE: NI) today announced an update on the implementation of a number of safety steps it is taking across the entirety of its seven-state operating area, including the installation of automatic shut-off devices to protect against over pressurization on its low-pressure systems.

Joe Hamrock, president and CEO of NiSource, said: “Safety is not just our top priority and a value we talk about—safety guides all of our actions. I am pleased to report we are taking tangible steps on our low-pressure systems across the company’s footprint, including the installation of automatic shut-off devices. We have dedicated ourselves to learning from the tragic events that took place in the Merrimack Valley last September, and all of us here at NiSource are doing everything we possibly can to ensure something like that won’t happen again.”

Since September 13th, NiSource has reviewed low-pressure systems across its operating area. This included a field survey and an engineering design review of regulator stations to determine how best to install additional over pressure protection systems, monitoring, and enhanced facility protection. Informed by this review, NiSource is strengthening safety systems to better safeguard against over pressurization and other incidents as outlined in the following steps:

  • Over pressurization protection devices: As previously announced, NiSource has committed to invest an initial estimate of $150 million to install automatic shut-off devices to protect against over pressurization on every low-pressure system across its seven-state operating area. Installation work has already begun. This is a fundamental shift in the design of the natural gas system and is a priority for the company. 
    Automatic shut-off devices provide an additional level of control and protection, operating like circuit-breakers. When the device senses an operating pressure that is too high or too low, it immediately shuts down natural gas to the system, regardless of the cause. Each of NiSource’s low-pressure distribution systems – containing approximately 2,000 regulators across the seven-state operating area – will have automatic shut-off devices in place to enhance customer safety.
  • Remote monitoring: NiSource has committed to adding additional remote monitoring capabilities on low-pressure systems, leveraging technology that will be installed throughout 2019. Building on existing monitoring capabilities, these will allow NiSource to see more comprehensive details on the current health and status of its systems as well as how those systems perform throughout the year, including alerts during any event of any abnormal system performance, and notifying of any automatic shut-off device activation. 
  • Safety Management System (SMS): NiSource has accelerated its process of implementing SMS across its seven-state operating area, in line with American Petroleum Institute Recommended Practice 1173. SMS will allow the company to proactively identify and mitigate risk and enhance its pipeline safety performance.
  • Damage prevention: NiSource has enhanced its damage prevention practices around low-pressure regulator stations, including field inspection and monitoring of excavators working for third parties. For example, when excavation work is being conducted in close proximity to regulator stations, a NiSource employee will always be present. 
  • Professional Engineer: In accordance with the National Transportation Safety Board (NTSB) urgent safety recommendations, NiSource has engaged a third party who will be providing certification on all construction work packets.

Additional details on the thorough review process following the September 13th event are below:

  • Field Survey: NiSource conducted a field survey of its low-pressure regulator systems to identify opportunities to enhance the safe and reliable operation of regulator station equipment.
  • Engineering Design: The company reviewed the engineering design of its regulator stations on low-pressure systems to determine how best to install additional over pressure protection systems, monitoring and enhanced facility protection.
  • Mapping: The company used the information from the field survey to begin adding new details to its electronic mapping system. This information is easily accessible by field and engineering personnel.

Hamrock concluded: “We have updated policies, procedures, system infrastructure and risk assessment protocols to actively prevent future incidents across our natural gas network. We continue to evaluate every opportunity to engineer fail-safe measures in our systems. This work is of the utmost importance to me and our entire team. This is our ongoing commitment to our customers and our communities.”

About NiSource
NiSource Inc. (NYSE: NI) is one of the largest fully-regulated utility companies in the United States, serving approximately 3.5 million natural gas customers and 500,000 electric customers across seven states through its local Columbia Gas and NIPSCO brands. Based in Merrillville, Indiana, NiSource’s approximately 8,000 employees are focused on safely delivering reliable and affordable energy to our customers and communities we serve. NiSource has been designated a World’s Most Ethical Company by the Ethisphere Institute since 2012, is a member of the Dow Jones Sustainability – North America Index and was named by Forbes magazine as the top-rated utility among America’s Best Large Employers in 2017. Additional information about NiSource, its investments in modern infrastructure and systems, its commitments and its local brands can be found at Follow us at, or NI-F

Cision View original content to download multimedia:

SOURCE NiSource Inc.

Modern Acupuncture Opens First Minnesota Clinic In Minnetonka

MINNETONKA, Minn., Feb. 22, 2019 /PRNewswire-PRWeb/ – Modern Acupunctureâ„¢, the first franchise to make the natural health and cosmetic benefits of acupuncture available to people in an accessible and affordable delivery, is now available in Minnetonka, Minn. This clinic marks the first location to open in Minnesota, and the 42nd in the nation.

Modern Acupuncture offers affordable memberships encouraging guests to add acupuncture to their regular health and wellness routines. There are two service plans provided, one for traditional acupuncture, and the other for cosmetic acupuncture. Depending on the treatment plan, options for additional sessions start as low as $30. Single walk-in sessions are also available.

In celebration of its opening, Modern Acupuncture will offer free initial treatments and grand opening specials on unlimited acupuncture plans through the month of March.

“I developed arthritis 25 years ago and sought out acupuncture for relief,” said Sandra Brown, Modern Acupuncture regional developer in Minnesota. “The disease is painful and has required me to have several joint replacements over the years. I began using acupuncture as an alternative to pain relief and immediately noticed a huge difference. I eventually drifted away from treatment because of the environment and time needed for treatments, until I came across Modern Acupuncture. Modern Acupuncture is a 30 minute treatment in a spa-like environment. While acupuncture has always been around here, it hasn’t always been this accessible and affordable. We look forward to bringing the natural healing of acupuncture to as any people as possible. “

Modern Acupuncture offers an enhanced acupuncture experience where unlike traditional acupuncture treatments, it does not require the removal of any clothing to access full-body health. Tiny needles (the size of a human hair) are carefully inserted into key points on the body to trigger an increase in blood flow to blocked or weak areas. When healthy blood flow is restored, the body’s natural healing abilities are activated, sending the body back into balance. Cosmetic acupuncture is no-tox beauty approach to anti-aging, acne, and an overall glow. A visit to Modern Acupuncture feels like a relaxing retreat, where guests can unwind and possibly even fall asleep all while experiencing the healing and/or cosmetic benefits of acupuncture. Sessions are typically 30 minutes or less, and walk-ins are welcome.

Upon entering Modern Acupuncture, guests are greeted by simplistic yet contemporary decor with calming colors and natural wood elements that create a spa-like environment, sending them into an instant state of tranquility. After a customized consultation with a Modern Acupuncture Zen Advisor, guests are taken back to the Zen Den, the treatment area outfitted with soundproof insulation, lounge-style recliners, glowing lanterns, peaceful music, and TV screens display stunning scenery from around the world, ensuring a multi-sensory experience while traditional or cosmetic acupuncture services are delivered. Guests leave with a customized treatment plan and a complimentary handcrafted organic tea blend.

“I experienced acupuncture for the first time for a painful shoulder injury,” said Dick Brown, Sandra’s husband and co-regional developer in Minnesota. “Two treatments, roughly two weeks apart, put me on the road to recovery. It was amazing to me that they treated my right shoulder with a needle as thin as a hair in my left foot.”

Acupuncture is administered by acupuncturists who have been certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM®) after completing a three-year masters degree from an accredited school. They are further trained in the specific method used at Modern Acupuncture by Robert Doane, EAMP, L.AC., DIPL., C.H., co-founder at Modern Acupuncture and world-renowned acupuncturist and educator.

The Minnetonka Clinic is located at 4733 County Road 101 inside Westwind Plaza. The location is open Monday – Friday from 10 a.m. – 7 p.m., and Saturday and Sunday from 10 a.m. – 4 p.m. For more information, or to book an appointment, visit

About Modern Acupunctureâ„¢
Modern Acupunctureâ„¢ is a franchise concept transforming the alternative medicine market and acupuncture industry. Offering an approachable, natural pathway, validated by thousands of years of practice to better health and wellbeing, Modern Acupunctureâ„¢ is the first franchise to deliver the natural health and cosmetic benefits of acupuncture in a retreat-like setting in highly accessible neighborhood locations across the country. Founded in 2016 and based in Scottsdale, Ariz., Modern Acupunctureâ„¢ currently offers area developer and franchisee opportunities to qualifying entrepreneurs. ACU Development, LLC is the franchisor of MA Modern Acupunctureâ„¢ franchise locations and an operator in some states. In California, Massachusetts, Nevada, New Jersey, New York, Tennessee, and Washington, ACU Development, LLC and its franchisees provide management services to affiliated professional acupuncture practices. For more information, please visit or call (480) 999-5505.


SOURCE Modern Acupuncture

Acid Reflux Product Provides Relief with Top Rating from

OVERLAND, Kan., Feb. 22, 2019 /PRNewswire-PRWeb/ – recently gave a best-in-class 5 star rating to Nexium, a leader among Acid Reflux products available for purchase online.

Millions of people struggle with Acid Reflux. The condition is caused when the stomach’s valve allows acid to move up into the esophagus, resulting in the familiar symptoms of heartburn, frequent hiccups and burping, nausea, and even problems swallowing. When these symptoms happen more than twice a week, it’s known as acid reflux disease or GERD (gastroesophageal reflux disease). Although most people’s first thought is to reduce or eliminate the immediate symptoms of acid reflux, the best approaches address both the cause and the results. Fortunately, there are a wide range of tested, proven products that deliver relief and healing.

“Nexium 24HR stops Acid Reflux in its tracks, offering round-the-clock relief,” according to Brian Dolezal of, LLC. “As one of several products on the market that use esomeprazole, a well-known proton pump inhibitor, Nexium reduces the amount of acid in the stomach. It’s designed to be taken over the course of two weeks as a once-daily capsule or tablet, delivering long-lasting relief of heartburn and other symptoms of Acid Reflux. The ‘little purple pill’ is also the most frequently used by physicians and pharmacists. Best of all, Nexium is easily purchased online and at affordable prices: typically, less than $25 for three 14-day courses. For all of these reasons, Nexium earns our highest ranking among non-prescription Acid Reflux products in 2019.”

To find out more about Nexium and other Acid Reflux products, including reviews and comparison rankings, please visit the Acid Reflux category of at

About Nexium
Nexium (esomeprazole) is used to fight gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome. It is also used for the prevention and handling of gastric ulcers induced by pain-relieving NSAIDs. Nexium is available in several formulations (Nexium gastro-resistant granules for oral suspension, Nexium gastro-resistant Multi-Unit Pellet System (Nexium MUPS) tablets, and Nexium injection/infusion) with varying approved indications. The rights to over-the-counter Nexium were externalized to Pfizer Consumer Health in 2012.

About, LLC is a leading provider of reviews and rankings for thousands of consumer products and services. From Acid Reflux to Insomnia and Irritable Bowel Syndrome, delivers in-depth product evaluations in order to make purchasing decisions easier.



MCNC expands cybersecurity tools, services and personnel

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2019 /PRNewswire/ – MCNC, the technology nonprofit that builds, owns and operates the North Carolina Research and Education Network (NCREN), today announced continued growth and commitment to ensuring high-speed connections on NCREN meet the highest levels of security.

MCNC now offers a full range of advanced cybersecurity solutions including three new services: DNS Security Filtering, Continuous Monitoring and Risk Assessment, and Security Advisory Consulting. All of MCNC’s new or enhanced services build upon existing services such as Enhanced DDoS Protection, Managed firewall, and Web Content Filtering.

Industry-Leading Compliance
MCNC successfully completed a Service Organization Controls (SOC) Type II examination in 2018 and is expected to renew this high-level certification again this month. The SOC Type II standard verifies that MCNC is appropriately managing security risks and is serious about data protection and effective operations.

DNS Security Filtering
MCNC’s DNS Security Filtering is a cloud-based security service powered by Akamai’s Enterprise Threat Protector platform. The service protects against malware, phishing, botnet command and control, and DNS data exfiltration threats by automatically checking requested domains against Akamai’s real-time domain risk scoring engine. Domains and IP addresses associated with malicious sites will not be resolved, preventing users from accessing the malicious sites. It’s an easy-to-deploy, low-cost solution to help protect today’s infrastructure and users.

Continuous Monitoring and Risk Assessment (CMRA)
CMRA is an automated solution that scans a customer’s network hosts, identifies systems that may be vulnerable to compromise, calculates risks of those vulnerabilities, and prioritizes the issues for resolution based on likelihood and impact of exploitation. MCNC has activated this service for more than 60 NCREN customers to date with dozens more already expressing interest in it this year.

Security Advisory Consulting
MCNC cybersecurity professionals assist in all areas of information security and risk management. The team’s most popular service is the Cybersecurity Program Review, where MCNC evaluates a customer’s existing cybersecurity program. Using the results of the review, MCNC builds a plan to improve a customer’s security posture in a way that prioritizes the most critical cyber-risk areas.

Enhanced DDoS Protection
MCNC continues to invest in Distributed Denial of Service, or DDoS, auto-mitigation capabilities for NCREN. The NCREN backbone infrastructure has been updated with advanced traffic routing capabilities including multiple DDoS scrubbing centers deployed on the network. MCNC’s Enhanced DDoS Protection is now a standard part of NCREN services and is provided to network customers at no additional cost.

Experts Ready to Serve
The MCNC Security Team led by Chief Information Security Officer Chris Beal continues growing to meet the demand of NCREN customers. The team now includes Paul Conrad as a Senior Cybersecurity Engineer, Ruthy Mabe as Security Services Program Manager, and Sandon Nachmann and Jason Shirley as our Security Advisory Consultants; with additional plans to hire more industry experts throughout the year.

“MCNC has a rich history of developing and delivering innovative technology solutions and services,” said Beal. “Now that cybersecurity is an essential part of today’s technology-driven society, the organization continues to develop a portfolio of cybersecurity services to best serve the citizens of North Carolina as a trusted partner, advisor, and resource in the rapidly-changing cybersecurity landscape.”

In addition to cybersecurity, MCNC provides a vast portfolio of network-based technology services and community services to K-20 education, public safety, state and local government, not-for-profit health care, and research institutions across North Carolina. View these offerings on the MCNC Service Catalog.

About MCNC

MCNC is a technology nonprofit that builds, owns and operates the North Carolina Research and Education Network (NCREN), which has successfully served research, education, non-profit health care, public safety, libraries, and other community institutions with Internet connectivity and services for 35 years. NCREN is the fundamental broadband infrastructure for 750 of these institutions including all K-20 education in North Carolina. As one of the nation’s premier middle-mile fiber networks, MCNC leverages NCREN to customize Internet services and related applications for each customer while supporting private service providers in bringing cost-efficient connectivity to rural and underserved communities in North Carolina. Visit MCNC Social: Facebook, Twitter @MCNC, YouTube, LinkedIn.

Editorial Contact
Noah Garrett, NGC Communications, on behalf of MCNC: (252) 423.1277 or


Cision View original content:


Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer

 RALEIGH, N.C., Feb. 22, 2019 (GLOBE NEWSWIRE) — Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the departure of the Chief Executive Officer and member of the Board of Directors, Christopher Prior, Ph. D, in order to pursue other opportunities. The current Executive Chairman, Sandeep Laumas, M.D., has been appointed as Innovate’s Chief Executive Officer. Dr. Laumas served as the executive chairman of Innovate Biopharmaceuticals Inc. since 2014 and oversaw the company since its seed financing and listing on Nasdaq last year.

Dr. Prior noted, “I have the utmost confidence in the entire management team’s commitment and ability to bring much needed therapies to patients with unmet needs.�

Dr. Laumas commented, “Our team remains focused on meeting our business goals of having the first to market treatment for celiac disease and creating long-term value for our shareholders.�

The company also announced the hiring of Patrick Griffin, M.D., FACP, as Chief Medical Officer to focus on executing a celiac disease phase 3 trial after previously announcing his joining Innovate to lead clinical development on November 26, 2018.

About Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT):
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (NASH). In several diseases, including celiac disease, NASH, Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD), the intestinal barrier is dysfunctional with increased permeability.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our plans to raise capital, our operations and business strategy. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials; the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated; the lengthy and unpredictable nature of the drug approval process; and our ability to commercialize our product candidates if approved. These risks and uncertainties include, but may not be limited to, those described in our Quarterly Report on Form 10-Q filed with the SEC on November 13, 2018, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

SOURCE: Innovate Biopharmaceuticals, Inc.

Jennifer K. Zimmons, Ph.D.
Investor Relations
Tel: +1-917-214-3514